Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Tlhaloso e Khutšoanyane:

Lebitso la lik'hemik'hale: Lasofoxifene Tartrate

CAS: 190791-29-8

Ponahalo: Phofo e tšoeu ho isa ho e tšoeu

Chiral Purity: ≥99.0%Bohloeki: ≥98.0% (HPLC)

Kalafo ea Postmenopausal Osteoporosis

API Boleng bo Phahameng, Tlhahiso ea Khoebo

Inquiry: alvin@ruifuchem.com

Re romelle lengolo-tsoibila

Lintlha tsa Sehlahisoa

Lihlahisoa tse Amanang

Li-tag tsa Sehlahisoa

Tlhaloso:

Phepelo ea Moetsi e nang le Bohloeki bo Phahameng le Boleng bo tsitsitseng
Lebitso la lik'hemik'hale: Lasofoxifene Tartrate
CAS: 190791-29-8
Lasofoxifene Tartrate (CAS: 190791-29-8) kalafo ea Postmenopausal Osteoporosis

Lintho tsa Lik'hemik'hale:

Lebitso la Lik'hemik'hale	Lasofoxifene tartrate
Litlhaloso tse tšoanang	(5R,6S) -5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl) ethoxy]phenyl] -2-naphthalenol Tartrate Oporia
Nomoro ea CAS	190791-29-8
Nomoro ea KAtse	RF-API20
Boemo ba Setoko	Ka Setokong, Phatlalatso e Eketsehile ho fihla ho Makholo a Lik'hilograma
Foromo ea limolek'hule	C28H31NO2.ClH
Boima ba Molek'hule	450.019
Brand	Ruifu Chemical

Litlhaloso:

Ntho	Litlhaloso
Ponahalo	Phofo e tšoeu ho isa ho e tšoeu
Mongobo (KF)	≤0.50%
Litšepe tse boima	≤20ppm
Chiral Purity	≥99.0%
Mokhoa oa Bohloeki / Analysis	≥98.0% (HPLC)
Tahlehelo ka ho Omisa	≤0.50%
Masalla a ho Ignition	≤0.50%
Tekanyetso ea Teko	Pharmacopoeia ea Chaena (CP);Maemo a Khoebo
Tšebeliso	Motsoako o sebetsang oa Pharmaceutical (API);Osteoporosis ea Postmenopausal

Sephutheloana le Bobolokelo:

Sephutheloana: Botlolo, Aluminium foil bag, Cardboard drum, 25kg/Drum, kapa ho latela tlhoko ea moreki.

Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa khanya, mongobo le ho hlaseloa ke likokoanyana.

Melemo:

LBH:

Kopo:

Shanghai Ruifu Chemical Co., Ltd. ke moetsi ea ka sehloohong le mofani oa thepa ea Lasofoxifene Tartrate (CAS: 190791-29-8) e nang le boleng bo phahameng.
Lasofoxifene Tartrate ke moloko oa boraro, e seng steroidal selective estrogen receptor modulator (SERM).E tlama ka mokhoa o ikhethileng ho ERalpha ea motho ka boleng ba IC50 ba 1.5 nM mme e thibela tahlehelo ea masapo ho likhoto tse entsoeng ka mahe a linotsi.Lithutong tsa bongaka tsa postmenopausal osteoporosis, 0.5 mg / letsatsi lasofoxifene e ne e amahanngoa le likotsi tse fokotsehileng tsa ho robeha ha mokokotlo le mokokotlo oa mokokotlo, kankere ea matsoele ea ER-positive, lefu la pelo le stroke empa kotsi e eketsehileng ea liketsahalo tsa venous thromboembolic.Lasofoxifene e boetse e bontšitsoe hore e sebetsa e le agonist e fapaneng ho CB2 cannabinoid receptor, e bontšang bokhoni ba eona ba ho khutlisetsoa hape e le phekolo bakeng sa matšoao ao CB2 e leng sepheo sa eona.